SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Homology Medicines, Inc., of Class Action Lawsuit and Upcoming Deadline – FIXX – QNT Press Release


NEW YORK, May 3, 2022 /PRNewswire/ — Pomerantz LLP announces that a class action lawsuit has been filed against Homology Medicines, Inc. (“Homology” or the “Company”) (NASDAQ:FIXX) and certain of its officers. The class action, filed in the United States District Court for the Central District of Californiaand docketed under 22-cv-01968, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Homology securities between June 10, 2019 and February 18, 2022both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

If you are a shareholder who purchased…

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center